We performed clustering based on the CD8/FOXP3 ratio, PD-1 and PD-L1 immune checkpoint expression and stratified patients into 3 clusters with different prognostic markers to guide cancer immunotherapy (anti-PD-1/PD-L1 therapy or targeting of Treg cells). This evidence concerns the gene CD8A and cancer.